Top

Published in:

Open Access 01-04-2008 | Research article

Evaluation of the current knowledge limitations in breast cancer research: a gap analysis

Authors: Alastair Thompson, Keith Brennan, Angela Cox, Julia Gee, Diana Harcourt, Adrian Harris, Michelle Harvie, Ingunn Holen, Anthony Howell, Robert Nicholson, Michael Steel, Charles Streuli, Breast Cancer Campaign Gap Analysis Meeting (2 November 2006, London, UK)

Published in: Breast Cancer Research | Issue 2/2008

Abstract

Background

A gap analysis was conducted to determine which areas of breast cancer research, if targeted by researchers and funding bodies, could produce the greatest impact on patients.

Methods

Fifty-six Breast Cancer Campaign grant holders and prominent UK breast cancer researchers participated in a gap analysis of current breast cancer research. Before, during and following the meeting, groups in seven key research areas participated in cycles of presentation, literature review and discussion. Summary papers were prepared by each group and collated into this position paper highlighting the research gaps, with recommendations for action.

Results

Gaps were identified in all seven themes. General barriers to progress were lack of financial and practical resources, and poor collaboration between disciplines. Critical gaps in each theme included: (1) genetics (knowledge of genetic changes, their effects and interactions); (2) initiation of breast cancer (how developmental signalling pathways cause ductal elongation and branching at the cellular level and influence stem cell dynamics, and how their disruption initiates tumour formation); (3) progression of breast cancer (deciphering the intracellular and extracellular regulators of early progression, tumour growth, angiogenesis and metastasis); (4) therapies and targets (understanding who develops advanced disease); (5) disease markers (incorporating intelligent trial design into all studies to ensure new treatments are tested in patient groups stratified using biomarkers); (6) prevention (strategies to prevent oestrogen-receptor negative tumours and the long-term effects of chemoprevention for oestrogen-receptor positive tumours); (7) psychosocial aspects of cancer (the use of appropriate psychosocial interventions, and the personal impact of all stages of the disease among patients from a range of ethnic and demographic backgrounds).

Conclusion

Through recommendations to address these gaps with future research, the long-term benefits to patients will include: better estimation of risk in families with breast cancer and strategies to reduce risk; better prediction of drug response and patient prognosis; improved tailoring of treatments to patient subgroups and development of new therapeutic approaches; earlier initiation of treatment; more effective use of resources for screening populations; and an enhanced experience for people with or at risk of breast cancer and their families. The challenge to funding bodies and researchers in all disciplines is to focus on these gaps and to drive advances in knowledge into improvements in patient care.

The CHEK2 Breast Cancer Case-Control Consortium: CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet. 2004, 74: 1175-1182. 10.1086/421251.PubMedCentralCrossRef

Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B, Jayatilake H, Barfoot R, Spanova K, McGuffog L, Evans DG, Eccles D, Breast Cancer Susceptibility Collaboration (UK), Easton DF, Stratton MR, Rahman N: ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet. 2006, 38: 873-875. 10.1038/ng1837.PubMedCrossRef

Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K, North B, McGuffog L, Evans DG, Eccles D, Breast Cancer Susceptibility Collaboration (UK), Easton DF, Stratton MR, Rahman N: Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet. 2006, 38: 1239-10.1038/ng1902.PubMedCrossRef

The Breast Cancer Association Consortium: Commonly studied SNPs and breast cancer: negative results from 12,000–32,000 cases and controls from the Breast Cancer Association Consortium. J Natl Cancer Inst. 2006, 98: 1382-1396.CrossRef

Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, Reed MW, Pooley KA, Scollen S, Baynes C, Ponder BA, Chanock S, Lissowska J, Brinton L, Peplonska B, Southey MC, Hopper JL, McCredie MR, Giles GG, Fletcher O, Johnson N, dos Santos Silva I, Gibson L, Bojesen SE, Nordestgaard BG, Axelsson CK, Torres D, Hamann U, Justenhoven C, Brauch H, Chang-Claude J, Kropp S, et al: A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet. 2007, 39: 352-358. 10.1038/ng1981. [Erratum: Nat Genet 2007, 39:688.]PubMedCrossRef

Stacey SN, Manolescu A, Sulem P, Rafnar T, Gudmundsson J, Gudjonsson SA, Masson G, Jakobsdottir M, Thorlacius S, Helgason A, Aben KK, Strobbe LJ, Albers-Akkers MT, Swinkels DW, Henderson BE, Kolonel LN, Le Marchand L, Millastre E, Andres R, Godino J, Garcia-Prats MD, Polo E, Tres A, Mouy M, Saemundsdottir J, Backman VM, Gudmundsson L, Kristjansson K, Bergthorsson JT, Kostic J, et al: Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet. 2007, 39: 865-869. 10.1038/ng2064.PubMedCrossRef

Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, Wang J, Yu K, Chatterjee N, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Hayes RB, Tucker M, Gerhard DS, Fraumeni JF, Hoover RN, Thomas G, Chanock SJ: Genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007, 39: 870-874. 10.1038/ng2075.PubMedPubMedCentralCrossRef

Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, Wareham N, Ahmed S, Healey CS, Bowman R, SEARCH collaborators, Meyer KB, Haiman CA, Kolonel LK, Henderson BE, Le Marchand L, Brennan P, Sangrajrang S, Gaborieau V, Odefrey F, Shen CY, Wu PE, Wang HC, Eccles D, Evans DG, Peto J: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007, 447: 1087-1093. 10.1038/nature05887.PubMedPubMedCentralCrossRef

Sharan SK, Morimatsu M, Albrecht U, Lim DS, Regel E, Dinh C, Sands A, Eichele G, Hasty P, Bradley A: Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature. 1997, 386: 804-810. 10.1038/386804a0.PubMedCrossRef

10.

Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, Ashley T, Livingston DM: Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell. 1997, 88: 265-275. 10.1016/S0092-8674(00)81847-4.PubMedCrossRef

11.

Polanowska J, Martin JS, Garcia-Muse T, Petalcorin MI, Boulton SJ: A conserved pathway to activate BRCA1-dependent ubiquitylation at DNA damage sites. EMBO J. 2006, 25: 2178-2188. 10.1038/sj.emboj.7601102.PubMedPubMedCentralCrossRef

12.

Yu X, Fu S, Lai M, Baer R, Chen J: BRCA1 ubiquitinates its phosphorylation-dependent binding partner CtIP. Genes Dev. 2006, 20: 1721-1726. 10.1101/gad.1431006.PubMedPubMedCentralCrossRef

13.

Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, Persky N, Grompe M, Joenje H, Pals G, Ikeda H, Fox EA, D'Andrea AD: Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 2002, 297: 606-609. 10.1126/science.1073834.PubMedCrossRef

14.

Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, Jayatilake H, McGuffog L, Hanks S, Evans DG, Eccles D, Breast Cancer Susceptibility Collaboration (UK), Easton DF, Stratton MR: PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007, 39: 165-167. 10.1038/ng1959.PubMedCrossRef

15.

Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE: The consensus coding sequences of human breast and colorectal cancers. Science. 2006, 314: 268-274. 10.1126/science.1133427.PubMedCrossRef

16.

Huang HE, Chin SF, Ginestier C, Bardou VJ, Adélaïde J, Iyer NG, Garcia MJ, Pole JC, Callagy GM, Hewitt SM, Gullick WJ, Jacquemier J, Caldas C, Chaffanet M, Birnbaum D, Edwards PA: A recurrent chromosome breakpoint in breast cancer at the NRG1/neuregulin 1/heregulin gene. Cancer Res. 2004, 64: 6840-6844. 10.1158/0008-5472.CAN-04-1762.PubMedCrossRef

17.

Streuli C, Ed: Key stages of mammary gland development [Review series]. Breast Cancer Res. [http://breast-cancer-research.com/articles/review-series.asp?series=bcr_keystages]

18.

Ip MM, Asch BB: Methods in Mammary Gland Biology and Breast Cancer Research. 2000, New York: KluwerCrossRef

19.

Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, Wu L, Lindeman GJ, Visvader JE: Generation of a functional mammary gland from a single stem cell. Nature. 2006, 439: 84-88. 10.1038/nature04372.PubMedCrossRef

20.

Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, Li HI, Eaves CJ: Purification and unique properties of mammary epithelial stem cells. Nature. 2006, 439: 993-997.PubMed

21.

Fowler KJ, Walker F, Alexander W, Hibbs ML, Nice EC, Bohmer RM, Mann GB, Thumwood C, Maglitto R, Danks JA, Chetty R, Burgess AW, Dunn AR: A mutation in the epidermal growth factor receptor in waved-2 mice has a profound effect on receptor biochemistry that results in impaired lactation. Proc Natl Acad Sci USA. 1995, 92: 1465-1469. 10.1073/pnas.92.5.1465.PubMedPubMedCentralCrossRef

22.

Sternlicht MD, Sunnarborg SW, Kouros-Mehr H, Yu Y, Lee DC, Werb Z: Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin. Development. 2005, 132: 3923-3933. 10.1242/dev.01966.PubMedPubMedCentralCrossRef

23.

Johnston SR, Leary A: Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Drugs Today (Barc). 2006, 42: 441-453. 10.1358/dot.2006.42.7.985637.CrossRef

24.

Stylianou S, Clarke RB, Brennan K: Aberrant activation of notch signaling in human breast cancer. Cancer Res. 2006, 66: 1517-1525. 10.1158/0008-5472.CAN-05-3054.PubMedCrossRef

25.

Brennan KR, Brown AM: Wnt proteins in mammary development and cancer. J Mammary Gland Biol Neoplasia. 2004, 9: 119-131. 10.1023/B:JOMG.0000037157.94207.33.PubMedCrossRef

26.

Sachdev D, Yee D: Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer. J Mammary Gland Biol Neoplasia. 2006, 11: 27-39. 10.1007/s10911-006-9010-8.PubMedCrossRef

27.

Serra R, Crowley MR: Mouse models of transforming growth factor beta impact in breast development and cancer. Endocr Relat Cancer. 2005, 12: 749-760. 10.1677/erc.1.00936.PubMedCrossRef

28.

Watson CJ: Post-lactational mammary gland regression: molecular basis and implications for breast cancer. Expert Rev Mol Med. 2006, 8: 1-15.PubMedCrossRef

29.

Bon G, Folgiero V, Di Carlo S, Sacchi A, Falcioni R: Involvement of alpha6beta4 integrin in the mechanisms that regulate breast cancer progression. Breast Cancer Res. 2007, 9: 203-10.1186/bcr1651.PubMedPubMedCentralCrossRef

30.

Sternlicht MD: Key stages in mammary gland development: the cues that regulate ductal branching morphogenesis. Breast Cancer Res. 2006, 8: 201-10.1186/bcr1368.PubMedCrossRef

31.

Schwertfeger KL, Rosen JM, Cohen DA: Mammary gland macrophages: pleiotropic functions in mammary development. J Mammary Gland Biol Neoplasia. 2006, 11: 229-238. 10.1007/s10911-006-9028-y.PubMedCrossRef

32.

Katz E, Streuli CH: The extracellular matrix as an adhesion checkpoint for mammary epithelial function. Int J Biochem Cell Biol. 2006, 39: 715-726. 10.1016/j.biocel.2006.11.004.PubMedCrossRef

33.

Aranda V, Haire T, Nolan ME, Calarco JP, Rosenberg AZ, Fawcett JP, Pawson T, Muthuswamy SK: Par6-aPKC uncouples ErbB2 induced disruption of polarized epithelial organization from proliferation control. Nat Cell Biol. 2006, 8: 1235-1245. 10.1038/ncb1485.PubMedCrossRef

34.

Larue L, Bellacosa A: Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene. 2005, 24: 7443-7454. 10.1038/sj.onc.1209091.PubMedCrossRef

35.

Sleeman KE, Kendrick H, Ashworth A, Isacke CM, Smalley MJ: CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells. Breast Cancer Res. 2006, 8: R7-10.1186/bcr1371.PubMedCrossRef

36.

Asselin-Labat ML, Shackleton M, Stingl J, Vaillant F, Forrest NC, Eaves CJ, Visvader JE, Lindeman GJ: Steroid hormone receptor status of mouse mammary stem cells. J Natl Cancer Inst. 2006, 98: 1011-1014.PubMedCrossRef

37.

Jonker JW, Freeman J, Bolscher E, Musters S, Alvi AJ, Titley I, Schinkel AH, Dale TC: Contribution of the ABC transporters Bcrp1 and Mdr1a/1b to the side population phenotype in mammary gland and bone marrow of mice. Stem Cells. 2005, 23: 1059-1065. 10.1634/stemcells.2005-0150.PubMedCrossRef

38.

Zhang M, Rosen JM: Stem cells in the etiology and treatment of cancer. Curr Opin Genet Dev. 2006, 16: 60-64. 10.1016/j.gde.2005.12.008.PubMedCrossRef

39.

Green KA, Streuli CH: Apoptosis regulation in the mammary gland. Cell Mol Life Sci. 2004, 61: 1867-1883. 10.1007/s00018-004-3366-y.PubMedCrossRef

40.

Watson CJ: Involution: apoptosis and tissue remodelling that convert the mammary gland from milk factory to a quiescent organ. Breast Cancer Res. 2006, 8: 203-10.1186/bcr1401.PubMedPubMedCentralCrossRef

41.

Polyak K: Pregnancy and breast cancer: the other side of the coin. Cancer Cell. 2006, 9: 151-153. 10.1016/j.ccr.2006.02.026.PubMedCrossRef

42.

Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, Lorenz K, Lee EH, Barcellos-Hoff MH, Petersen OW, Gray JW, Bissell MJ: The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol. 2007, 1: 84-96. 10.1016/j.molonc.2007.02.004.PubMedPubMedCentralCrossRef

43.

Debnath J, Brugge JS: Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer. 2005, 5: 675-688. 10.1038/nrc1695.PubMedCrossRef

44.

Clarke RB: Isolation and characterization of human mammary stem cells. Cell Prolif. 2005, 38: 375-386. 10.1111/j.1365-2184.2005.00357.x.PubMedCrossRef

45.

Wolf K, Friedl P: Molecular mechanisms of cancer cell invasion and plasticity. Br J Dermatol. 2006, 11-15. 10.1111/j.1365-2133.2006.07231.x. Suppl 1

46.

Sidani M, Wyckoff J, Xue C, Segall JE, Condeelis J: Probing the microenvironment of mammary tumors using multiphoton microscopy. J Mammary Gland Biol Neoplasia. 2006, 11: 151-163. 10.1007/s10911-006-9021-5.PubMedCrossRef

47.

Hennighausen L, Robinson GW: Information networks in the mammary gland. Nat Rev Mol Cell Biol. 2005, 6: 715-725. 10.1038/nrm1714.PubMedCrossRef

48.

Teulière J, Faraldo MM, Deugnier MA, Shtutman M, Ben-Ze'ev A, Thiery JP, Glukhova MA: Targeted activation of beta-catenin signaling in basal mammary epithelial cells affects mammary development and leads to hyperplasia. Development. 2005, 132: 267-277. 10.1242/dev.01583.PubMedCrossRef

49.

Moody SE, Perez D, Pan TC, Sarkisian CJ, Portocarrero CP, Sterner CJ, Notorfrancesco KL, Cardiff RD, Chodosh LA: The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell. 2005, 8: 197-209. 10.1016/j.ccr.2005.07.009.PubMedCrossRef

50.

DasGupta R, Fuchs E: Multiple roles for activated LEF/TCF transcription complexes during hair follicle development and differentiation. Development. 1999, 126: 4557-4568.PubMed

51.

Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, Carey L, Richardson A, Weinberg RA: Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci USA. 2004, 101: 4966-4971. 10.1073/pnas.0401064101.PubMedPubMedCentralCrossRef

52.

Rennstam K, Hedenfalk I: High-throughput genomic technology in research and clinical management of breast cancer. Molecular signatures of progression from benign epithelium to metastatic breast cancer. Breast Cancer Res. 2006, 8: 213-10.1186/bcr1528.PubMedPubMedCentralCrossRef

53.

Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell. 1996, 87: 159-170. 10.1016/S0092-8674(00)81333-1.PubMedCrossRef

54.

Sims AH, Ong KR, Clarke RB, Howell A: High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic?. Breast Cancer Res. 2006, 8: 214-10.1186/bcr1605.PubMedPubMedCentralCrossRef

55.

Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M, Osborne CK: Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol. 2005, 10-20. 10.1007/s00280-005-0108-2. Suppl 1

56.

Britton DJ, Hutcheson IR, Knowlden JM, Barrow D, Giles M, McClelland RA, Gee JM, Nicholson RI: Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat. 2006, 96: 131-146. 10.1007/s10549-005-9070-2.PubMedCrossRef

57.

Speirs V, Walker RA: New perspectives into the biological and clinical relevance of oestrogen receptors in the human breast. J Pathol. 2007, 211: 499-506. 10.1002/path.2130.PubMedCrossRef

58.

Nicholson RI, Hutcheson IR, Hiscox SE, Knowlden JM, Giles M, Barrow D, Gee JM: Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocr Relat Cancer. 2005, S29-36. 10.1677/erc.1.00991. Suppl 1

59.

Anand S, Penrhyn-Lowe S, Venkitaraman AR: AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell. 2003, 3: 51-62. 10.1016/S1535-6108(02)00235-0.PubMedCrossRef

60.

Sledge GW: VEGF-targeting therapy for breast cancer. J Mammary Gland Biol Neoplasia. 2005, 10: 319-323. 10.1007/s10911-006-9005-5.PubMedCrossRef

61.

Hiscox S, Morgan L, Barrow D, Dutkowskil C, Wakeling A, Nicholson RI: Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). Clin Exp Metastasis. 2004, 21: 201-212. 10.1023/B:CLIN.0000037697.76011.1d.PubMedCrossRef

62.

Jones JL, JA Shaw, JH Pringle, Walker RA: Primary breast myoepithelial cells exert an invasion-suppressor effect on breast cancer cells via paracrine downregulation of MMP expression in fibroblasts and tumour cells. J Pathol. 2003, 201: 562-572. 10.1002/path.1483.PubMedCrossRef

63.

Adams M, Jones JL, Walker RA, Pringle JH, Bell SC: Changes in Tenascin-C isoforms expression in invasive and preinvasive breast disease. Cancer Res. 2002, 62: 3289-3297.PubMed

64.

Barnes N, Haywood P, Flint P, Knox WF, Bundred NJ: Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br J Cancer. 2006, 94: 253-258. 10.1038/sj.bjc.6602932.PubMedPubMedCentralCrossRef

65.

Kamb A: What's wrong with our cancer models?. Nat Rev Drug Discov. 2005, 4: 161-165. 10.1038/nrd1635.PubMedCrossRef

66.

Cleator SJ, Powles TJ, Dexter T, Fulford L, Mackay A, Smith IE, Valgeirsson H, Ashworth A, Dowsett M: The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis. Breast Cancer Res. 2006, 8: R32-10.1186/bcr1506.PubMedPubMedCentralCrossRef

67.

Foulkes WD: BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer. 2006, 5: 135-142. 10.1007/s10689-005-2832-5.PubMedCrossRef

68.

Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J, for the Scandinavian Breast Group Trial 9401: Topoisomerase II alpha gene amplification predicts favourable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol. 2006, 24: 2428-2436. 10.1200/JCO.2005.02.9264.PubMedCrossRef

69.

Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, Nicholson RI: Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer. 2005, S99-S111. 10.1677/erc.1.01005. Suppl 1

70.

Sarwar N, Kim JS, Jiang J, Peston D, Sinnett HD, Madden P, Gee JM, Nicholson RI, Lykkesfeldt AE, Shousha S, Coombes RC, Ali S: Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression. Endocr Relat Cancer. 2006, 13: 851-861. 10.1677/erc.1.01123.PubMedCrossRef

71.

Leake R, Barnes D, Pinder S, Ellis I, Anderson L, Anderson T, Adamson R, Rhodes T, Miller K, Walker R: Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC. J Clin Pathol. 2000, 53: 634-635. 10.1136/jcp.53.8.634.PubMedPubMedCentralCrossRef

72.

Ellis IO, Bartlett J, Dowsett M, Humphreys S, Jasani B, Miller K, Pinder SE, Rhodes A, Walker R: Best Practice No 176: updated recommendations for HER2 testing in the UK. J Clin Pathol. 2004, 57: 233-237. 10.1136/jcp.2003.007724.PubMedPubMedCentralCrossRef

73.

Walker RA: Quantification of immunohistochemistry – issues concerning methods, utility and semiquantitative assessment I. Histopathology. 2006, 49: 406-410. 10.1111/j.1365-2559.2006.02514.x.PubMedCrossRef

74.

Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast. Nature. 2000, 406: 747-752. 10.1038/35021093.PubMedCrossRef

75.

Gee JM, Shaw VE, Hiscox SE, McClelland RA, Rushmere NK, Nicholson RI: Deciphering anti hormone-induced compensatory mechanisms in breast cancer and their therapeutic implications. Endocr Relat Cancer. 2006, S77-88. 10.1677/erc.1.01274. Suppl 1

76.

Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, Knowlden JM, McClelland RA, Jordan N, Wakeling AE, Nicholson RI: The anti-epidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves anti-hormone response and prevents development of resistance in breast cancer in vitro. Endocrinology. 2003, 144: 5105-5117. 10.1210/en.2003-0705.PubMedCrossRef

77.

Hutcheson IR, Knowlden JM, Jones HE, Burmi RS, McClelland RA, Barrow D, Gee JM, Nicholson RI: Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy. Endocr Relat Cancer. 2006, S89-97. 10.1677/erc.1.01279. Suppl 1

78.

Tiligada E, Miligkos V, Delitheos A: Cross-talk between cellular stress, cell cycle and anticancer agents: mechanistic aspects. Curr Med Chem Anticancer Agents. 2002, 2: 553-566. 10.2174/1568011023353976.PubMedCrossRef

79.

Dent P, Yacoub A, Contessa J, Caron R, Amorino G, Valerie K, Hagan MP, Grant S, Schmidt-Ullrich R: Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res. 2003, 159: 283-300. 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2.PubMedCrossRef

80.

Rodger A, Stebbing J, Thompson AM: Breast cancer (non-metastatic). Clin Evid. 2006, 15: 2360-2392.

81.

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD, Herceptin Adjuvant (HERA) Trial Study Team: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005, 353: 1659-1672. 10.1056/NEJMoa052306.PubMedCrossRef

82.

Dixon JM: The scientific value of preoperative studies and how they can be used to identify biomarkers. Breast Cancer Res Treat. 2004, 87: S19-S26. 10.1007/s10549-004-1579-2.PubMedCrossRef

83.

Purdie CA: Sentinel lymph node biopsy: review of the literature and guidelines for pathological handling and reporting. Curr Diagn Pathol. 2007, 13: 106-115. 10.1016/j.cdip.2006.12.005.CrossRef

84.

Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, Bines J, Mook S, Decker N, Ravdin P, Therasse P, Rutgers E, van 't Veer LJ, Piccart M, TRANSBIG consortium: TRANSBIG consortium. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol. 2006, 3: 540-551. 10.1038/ncponc0591.PubMedCrossRef

85.

Goulding H, Pinder S, Cannon P, Pearson D, Nicholson R, Snead D, Bell J, Elston CW, Robertson JF, Blamey RW, Ellis IO: A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin fixed tissue samples. Hum Pathol. 1995, 26: 291-294. 10.1016/0046-8177(95)90060-8.PubMedCrossRef

86.

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S: Repeated observations of breast tumor subtypes in independent gene expression datasets. Proc Natl Acad Sci USA. 2003, 100: 8418-8423. 10.1073/pnas.0932692100.PubMedPubMedCentralCrossRef

87.

Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO: High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer. 2005, 116: 340-350. 10.1002/ijc.21004.PubMedCrossRef

88.

Bartlett JM, Ibrahim M, Jasani B, Morgan JM, Ellis I, Kay E, Magee H, Barnett S, Miller K: External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme. J Clin Pathol. 2007, 60: 816-819. 10.1136/jcp.2006.040840.PubMedCrossRef

89.

Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005, 365: 60-62. 10.1016/S0140-6736(05)74803-0.PubMedCrossRef

90.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N, National Surgical Adjuvant Breast and Bowel Project (NSABP): Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006, 295: 2727-2741. 10.1001/jama.295.23.joc60074.PubMedCrossRef

91.

Amir E, Evans DG, Shenton A, Lalloo F, Moran A, Boggis C, Wilson M, Howell A: Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet. 2003, 40: 807-814. 10.1136/jmg.40.11.807.PubMedPubMedCentralCrossRef

92.

McCormack VA, dos Santos Silva I: Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006, 15: 1159-1169. 10.1158/1055-9965.EPI-06-0034.PubMedCrossRef

93.

Doll R, Peto R: The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst. 1981, 66: 1191-1308.PubMed

94.

Bingham SA, Luben R, Welch A, Wareham N, Khaw KT, Day N: Are imprecise methods obscuring a relation between fat and breast cancer?. Lancet. 2003, 362: 212-214. 10.1016/S0140-6736(03)13913-X.PubMedCrossRef

95.

Freedman LS, Potischman N, Kipnis V, Midthune D, Schatzkin A, Thompson FE, Troiano RP, Prentice R, Patterson R, Carroll R, Subar AF: A comparison of two dietary instruments for evaluating the fat-breast cancer relationship. Int J Epidemiol. 2006, 35: 1011-1021. 10.1093/ije/dyl085.PubMedCrossRef

96.

Low YL, Dunning AM, Dowsett M, Luben RN, Khaw KT, Wareham NJ, Bingham SA: Implications of gene-environment interaction in studies of gene variants in breast cancer: an example of dietary isoflavones and the D356N polymorphism in the sex hormone-binding globulin gene. Cancer Res. 2006, 66: 8980-8983. 10.1158/0008-5472.CAN-06-2432.PubMedCrossRef

97.

Harvie M, Howell A, Vierkant RA, Kumar N, Cerhan JR, Kelemen LE, Folsom AR, Sellers TA: Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev. 2005, 14: 656-661. 10.1158/1055-9965.EPI-04-0001.PubMedCrossRef

98.

Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE: Adult weight change and risk of postmenopausal breast cancer. JAMA. 2006, 296: 193-201. 10.1001/jama.296.2.193.PubMedCrossRef

99.

Harvie M, Howell A: Energy balance adiposity and breast cancer – energy restriction strategies for breast cancer prevention. Obes Rev. 2006, 7: 33-47. 10.1111/j.1467-789X.2006.00207.x.PubMedCrossRef

100.

International Agency for Research on Cancer Expert Group: Breast Cancer Screening. IARC Handbooks of Cancer Prevention. 2002, Lyon, France: IARC, 7: 248-

101.

Maurice A, Evans DG, Shenton A, Ashcroft L, Baildam A, Barr L, Byrne G, Bundred N, Boggis C, Wilson M, Duffy SW, Howell A: Screening younger women with a family history of breast cancer – does early detection improve outcome?. Eur J Cancer. 2006, 42: 1385-1390. 10.1016/j.ejca.2006.01.055.PubMedCrossRef

102.

Gui GP, Kadayaprath G, Darhouse N, Self J, Ward A, A'Hern R, Eeles R: Clinical outcome and service implications of screening women at increased breast cancer risk from a family history. Eur J Surg Oncol. 2006, 32: 719-724. 10.1016/j.ejso.2006.05.002.PubMedCrossRef

103.

Cortesi L, Turchetti D, Marchi I, Fracca A, Canossi B, Rachele B, Silvia R, Rita PA, Pietro T, Massimo F: Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience. BMC Cancer. 2006, 6: 210-10.1186/1471-2407-6-210.PubMedPubMedCentralCrossRef

104.

Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, Gilbert FJ, Griebsch I, Hoff RJ, Kessar P, et al: Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet. 2005, 365: 1769-1778. 10.1016/S0140-6736(05)66646-9.PubMedCrossRef

105.

Kroenke CH, Chen WY, Rosner B, Holmes MD: Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol. 2005, 23: 1370-1378. 10.1200/JCO.2005.01.079.PubMedCrossRef

106.

Camoriano JK, Loprinzi CL, Ingle JN, Therneau TM, Krook JE, Veeder MH: Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol. 1990, 8: 1327-1334.PubMed

107.

Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamounas EP: Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst. 2003, 95: 1467-1476.PubMedPubMedCentralCrossRef

108.

Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, Goodman MT, Giuliano AE, Karanja N, McAndrew P, Hudis C, Butler J, Merkel D, Kristal A, Caan B, Michaelson R, Vinciguerra V, Del Prete S, Winkler M, Hall R, Simon M, Winters BL, Elashoff RM: Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst. 2006, 98: 1767-1776.PubMedCrossRef

109.

Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA: Physical activity and survival after breast cancer diagnosis. JAMA. 2005, 293: 2479-2486. 10.1001/jama.293.20.2479.PubMedCrossRef

110.

McNeely ML, Campbell KL, Rowe BH, Klassen TP, Mackey JR, Courneya KS: Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. CMAJ. 2006, 175: 34-41.PubMedPubMedCentralCrossRef

111.

Julian-Reynier C, Welkenhuysen M, Hagoel L, Decruyenaere M, Hopwood P, CRISCOM Working Group: Risk communication strategies: state of the art and effectiveness in the context of cancer genetic services. Eur J Hum Genet. 2003, 11: 725-736. 10.1038/sj.ejhg.5201037.PubMedCrossRef

112.

Lostumbo L, Carbine N, Wallace J, Ezzo J: Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. 2004, 4: CD002748-

113.

Brett J, Bankhead C, Henderson B, Watson E, Austoker J: The psychological impact of mammographic screening. A systematic review. Psychooncology. 2005, 14: 917-938. 10.1002/pon.904.PubMedCrossRef

114.

Brennan J, Moynihan C: Cancer in Context: A Practical Guide to Supportive Care. 2004, Oxford: Oxford University Press

115.

Wagner CD, Bigatti SM, Storniolo AM: Quality of life of husbands of women with breast cancer. Psychooncology. 2006, 15: 109-120. 10.1002/pon.928.PubMedCrossRef

116.

Moyer A: Psychological outcomes of breast-conserving surgery versus mastectomy: a meta-analytic review. Health Psychol. 1997, 16: 284-298. 10.1037/0278-6133.16.3.284.PubMedCrossRef

117.

Harcourt DM, Rumsey NJ, Ambler NR, Cawthorn SJ, Reid CD, Maddox PR, Kenealy JM, Rainsbury RM, Umpleby HC: The psychological impact of mastectomy with or without immediate breast reconstruction: a prospective, multi-centred study. Plast Reconstr Surg. 2003, 111: 1060-1068. 10.1097/01.PRS.0000046249.33122.76.PubMedCrossRef

118.

Scott JT, Harmsen M, Prictor MJ, Entwistle VA, Sowden AJ, Watt I: Recordings or summaries of consultations for people with cancer. Cochrane Database Syst Rev. 2003, 2: CD001539-

119.

Fallowfield L, Jenkins V, Farewell V, Solis-Trapala I: Enduring impact of communication skills training: results of a 12-month follow-up. Br J Cancer. 2003, 89: 1445-1449. 10.1038/sj.bjc.6601309.PubMedPubMedCentralCrossRef

120.

Main DS, Nowels CT, Cavender TA, Etschmaier M, Steiner JF: A qualitative study of work and work return in cancer survivors. Psychooncology. 2005, 14: 992-1004. 10.1002/pon.913.PubMedCrossRef

121.

122.

Sheard T, Maguire P: The effect of psychological interventions on anxiety and depression in cancer patients: results of two meta-analyses. Br J Cancer. 1999, 80: 1770-1780. 10.1038/sj.bjc.6690596.PubMedPubMedCentralCrossRef

123.

Corner J, Wright D, Foster C, Gunaratnam Y, Hopkinson J, Okamoto I: The Macmillan Listening Study: Listening to the Views of People Affected by Cancer about Cancer Research. Published Report. 2006, London: Macmillan Cancer Support

124.

Schofield P, Carey M, Bonevski B, Sanson-Fisher R: Barriers to the provision of evidence-based psychosocial care in oncology. Psychooncology. 2006, 15: 863-872. 10.1002/pon.1017.PubMedCrossRef

125.

Northouse LL, Mood D, Kershaw T, Schafenacker A, Mellon S, Walker J, Galvin E, Decker V: Quality of life of women with recurrent breast cancer and their family members. J Clin Oncol. 2002, 20: 4050-4064. 10.1200/JCO.2002.02.054.PubMedCrossRef

Title: Evaluation of the current knowledge limitations in breast cancer research: a gap analysis
Authors: Alastair Thompson
Keith Brennan
Angela Cox
Julia Gee
Diana Harcourt
Adrian Harris
Michelle Harvie
Ingunn Holen
Anthony Howell
Robert Nicholson
Michael Steel
Charles Streuli
Breast Cancer Campaign Gap Analysis Meeting (2 November 2006, London, UK)
Publication date: 01-04-2008
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue 2/2008
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr1983

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2008

NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models

Cancer stem cell heterogeneity in hereditary breast cancer

Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction

Breast cancer metastasis: a microRNA story

Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer

Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health–AARP Diet and Health Study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer